Overcoming Two Major Obstacles That Limit the Effectiveness of Cancer Immunotherapies
We are advancing two innovative platform technologies designed to overcome two major obstacles that limit the effectiveness of immunotherapies in treating cancer.
- Primary or Innate Resistance related to tumor intrinsic factors associated with insufficient tumor immunogenicity, allowing tumors to escape immune recognition and attack.
- Secondary or Acquired Resistance resulting from extrinsic factors related to the Tumor Microenvironment, the highly immunosuppressive area surrounding the tumor that is capable of deactivating immune cells and responses against the tumor.